Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification

J Thorac Oncol. 2016 Jul;11(7):e83-5. doi: 10.1016/j.jtho.2016.02.021. Epub 2016 Mar 14.

Authors

Justin F Gainor¹, Matthew J Niederst², Jochen K Lennerz³, Ibiayi Dagogo-Jack², Sara Stevens², Alice T Shaw², Lecia V Sequist², Jeffrey A Engelman²

Affiliations

¹ Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: [email protected].
² Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
³ Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

PMID: 26988570
DOI: 10.1016/j.jtho.2016.02.021

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Crizotinib
ErbB Receptors / genetics*
Erlotinib Hydrochloride / administration & dosage
Female
Gene Amplification*
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics
Lung Neoplasms / pathology*
Mutation*
Prognosis
Proto-Oncogene Proteins c-met / genetics*
Pyrazoles / administration & dosage
Pyridines / administration & dosage

Substances

Pyrazoles
Pyridines
Crizotinib
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors
MET protein, human
Proto-Oncogene Proteins c-met